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Inflammatory signals associated with hemodialysis. excretion of cytokines, and certain co-morbid condition
Background. Inflammation is highly prevalent in chronic he- [6–8]. The hemodialysis procedure has also been sug-
modialysis patients. Because hemodialysis involves the contact gested as a potential source of inflammation in chronicof blood with “foreign” surfaces, and the documented activa-
hemodialysis patients.tion of several humoral and cellular pathways during the pro-
Several reports have documented the catabolic effectscedure, the hemodialysis procedure has been suggested as a
potential source of inflammation in this patient population. Ear- of a hemodialysis procedure [9, 10]. This effect has been
lier studies did not provide clear-cut evidence of the potential explained by the loss of amino acids and protein into the
contribution of the hemodialysis procedure to inflammation, dialysate and by the blood-membrane interaction [11, 12].as assessed by markers of inflammation such as cytokine levels
Earlier studies have shown modest changes in selectedand acute-phase protein production.
cytokine concentrations before and after hemodialysis,Methods. Nine patients were studied using primed-constant
infusion of l-(l-13C) leucine 2 hours before, during, and 2 hours particularly with the use of bioincompatible membranes
after a single hemodialysis session. We evaluated the effects [13–21]. Direct evidence of acute-phase response to the
of hemodialysis on induction of interleukin-6 (IL-6) production
hemodialysis procedure, especially with the use of bio-as well as the fractional synthetic rates (FSR) of albumin and
compatible hemodialysis membranes, is controversial. Infibrinogen, two well-known acute-phase proteins.
Results. During hemodialysis, albumin FSR and fibrinogen order to explore this issue further, we evaluated the direct
FSR increased significantly compared to the measurements effects of the hemodialysis procedure on the induction
obtained during baseline period. During this period, albumin of inflammatory reaction by serial assessments of inter-
and fibrinogen FSR increased 64% and 34%, respectively, com-
leukin-6 (IL-6) concentration and the fractional syntheticpared to baseline (P  0.05). While the increase in IL-6 con-
rates (FSR) of two acute-phase reactants, namely serumcentration was modest during hemodialysis (14%), the levels
further increased at the end of the 2-hour post-hemodialysis albumin and serum fibrinogen before, during, and after
period (68% higher compared to baseline, P  0.05). Fibrino- hemodialysis. IL-6 is considered to be a major regulator
gen FSR also demonstrated a further increase during the post- of many of the acute phase proteins including C-reactive
dialysis period (17% higher compared to the intradialytic pe-
protein (CRP), albumin, and fibrinogen [22–24]. In addi-riod and 58% higher compared to baseline), while albumin FSR
tion, fibrinogen levels are often elevated in hemodialysisstabilized during this period.
Conclusions. The results provide clear evidence of hemodi- patients and have been found to predict mortality [3,
alysis-induced inflammatory response. The process is most no- 25, 26]. Of note, fibrinogen FSR is increased in trauma
table during the 2-hour post-hemodialysis period. patients who have high levels of inflammatory markers
[27]. The results of our study indicate that the hemodialy-
sis procedure induces an inflammatory response as evi-
Chronic inflammation is highly prevalent in end-stage denced by the increase in fibrinogen FSR observed dur-
renal disease (ESRD) patients [1–3]. It is also strongly ing hemodialysis followed by concomitant increases in
correlated with clinical outcome [3–5]. Chronic inflam- both IL-6 concentrations and fibrinogen FSR during the
mation can be related to multiple factors in ESRD pa- 2-hour post-hemodialysis period.
tients, including underlying uremic conditions, reduced
METHODS
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Patients were recruited from Vanderbilt UniversityReceived for publication September 21, 2001
Outpatient Dialysis Clinic. All study patients were onand in revised form April 4, 2002
Accepted for publication May 6, 2002 chronic hemodialysis treatment for a minimum of 6
months and were clinically stable without any overt ac- 2002 by the International Society of Nephrology
1408
Caglar et al: Hemodialysis-induced inflammation 1409
Fig. 1. Experimental design. Each study con-
sisted of a 120-minute equilibration period
(150 to 30 minutes), a 30-minute basal pe-
riod, a 240-minute hemodialysis period (0 to
240 minutes), and a 120-minute post-dialysis
period. The dashes indicate blood sampling
time points.
tive inflammatory or infectious disease such as vascular patients. Six healthy individuals were studied in a fasting
access infections, overt periodontal disease; none of these state to serve as a control group for baseline IL-6 mea-
patients were hospitalized within 3 months prior to study surements.
initiation. Patients on nonsteroidal anti-inflammatory drugs
(NSAIDs) or glucocorticoids were not included in the Isotope infusion
study. The Institutional Review Board of Vanderbilt Uni- Albumin FSR and fibrinogen FSR were determined
versity approved the study protocol and written in- by isotope infusion technique according to published
formed consent was obtained from each patient. methods [28–30]. A primed constant infusion of l-(1-13C)
leucine was the method of choice to analyze amino acidStudy design
turnover before, during, and after a single hemodialysisThe study was a prospective design with patients serv-
procedure. The isotope was infused via a dialysis needleing as their own controls. A schematic diagram of the study
placed in the venous side of arteriovenous (AV) shunt.protocol is depicted in Figure 1. Within a week prior to
The arterial side of the AV shunt was used for arterialeach study, each patient had dual-energy x-ray absorpti-
blood sampling. Recirculation of AV shunt, as well as vas-ometry and bioelectrical impedance analysis to estimate
cular access blood flow to assess for possible stenosis,lean body mass and body fat mass. The subjects were ad-
was measured prior to each study in every patient. Theremitted to the General Clinical Research Center (GCRC)
was no recirculation within the AV shunt and blood fromthe day before the study. They were given an evening
venous and arterial sides of the shunt was not mixed,meal meeting nutrient requirements and remained fast-
providing appropriate routes for infusion of isotopes anding after 8:00 p.m. At approximately 6:00 a.m. on the
next day, the metabolic study was initiated by starting blood sampling, respectively. Following collection of
an infusion of isotopes. Prior to infusion of isotopes, blood to determine isotopic backgrounds (150 min-
blood samples were obtained for measurement of serum utes), the study was initiated with a bolus infusion of
concentrations of the following biochemical parameters: l-(1-13C) leucine (7.2mol/kg) to prime the leucine pool.
albumin, prealbumin, transferrin, cholesterol, total bi- To achieve a steady-state level of leucine, a constant
carbonate, and CRP. Each study consisted of a 2-hour infusion of l-(1-13C) leucine (0.12 mol/kg · min) was
equilibration period, a 30-minute basal sampling period, continued throughout the remainder of the study.
a 4-hour dialysis period (their usual prescription) and a During the basal period, arterial and venous blood
2-hour post dialysis period. Dialysis prescription was the samples were taken every 15 minutes. At the conclusion
same for all study patients and consisted of blood flow
of the basal period, the patients were initiated on hemo-
of 400 mL/min and dialysate flow of 800 mL/min. All
dialysis, which lasted for 4 hours. One hour after ini-patients were dialyzed with new biocompatible mem-
tiation of hemodialysis, blood was collected every 30branes (Fresenius F-80A, Walnut Creek, CA, USA).
minutes from the arterial side of the AV shunt. AfterThe composition of the dialysate used during the study
hemodialysis was completed and patients were discon-was identical for all treatments and consisted of 139
nected from the machine, a 2-hour post-dialysis periodmEq/L sodium, 2 mEq/L potassium, 2.5 mEq/L calcium,
ensued. During the post-dialysis period, blood samples200 mg/dL glucose, and 39 mEq/L bicarbonate. Ultrafil-
were collected every 30 minutes, starting 1 hour aftertration rates were determined by the patients’ previously
completion of hemodialysis. Dialysate samples were ob-established “estimated dry weight.” Albumin FSR, fi-
tained to measure endotoxin levels at every other treat-brinogen FSR, and IL-6 concentrations were determined
ment. The endotoxin levels were consistently undetect-for the basal, hemodialysis, and post-dialysis periods.
Measurements for IL-6 were available only for eight able on all occasions.
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Analytical procedures
Plasma enrichments of (13C) ketoisocaproate (KIC)
were determined using gas chromatography/mass spec-
trometry (GC/MS; Hewlett-Packard 5890a GC and 5970
MS, San Fernando, CA, USA). Plasma was deproteinized
with 4% perchloric acid (PCA), and the supernatant was
passed over a cation exchange resin to separate the keto
and amino acids. The keto acids were further extracted
with methylene chloride and 0.5 mol/L ammonium hydrox-
ide [31]. After drying under nitrogen gas, the keto fraction
was derivatized [28] with N-methyl-N-(t-butyldimethyl-
silylation)-trifluoroacetamide containing 1% t-butyldi-
methylcholorosilane (MtBSTFA 1% t-BDMCS; Regis
Technologies, Inc., Morton Grove, IL, USA). The deriv- Fig. 2. Expired carbon dioxide (CO2) enrichments during the study.
atized samples were then analyzed with GC/MS for The data indicate steady-state conditions during each phase of the study
with slopes not statistically significantly different than zero.plasma KIC enrichments, using selected ion monitoring.
The major fragments analyzed for the t-BDMCS deriva-
tive of KIC and 13C-KIC were the (M-57) ion fragments
301 m/z and 302 m/z, respectively. The enrichment was tion isotope ratio mass spectrometry. Enrichment mea-
quantified in plasma as the ratio of 13C-KIC:KIC (ion surements were made in duplicate, and duplicates had
abundance of 301/302 m/z). Enrichment measurements a coefficient of variation of N  1%.
were made in duplicate, and duplicates had a coefficient The 13C combustion analyses were performed via Du-
of variation (N 3%). Breath 13CO2 was measured by mas combustion in a Europa ANCA-NT system and
isotope ratio mass spectrometry (Metabolic Solutions, subsequent isotope analysis in a Europa 20/20 Stable
Nashua, NH, USA). Isotope Analyzer (PDZ Europa, Cheshire, England).
Fibrinogen was precipitated from 2 mL plasma by This is a continuous-flow system (helium of 99.999% as
adding 40 L calcium chloride (CaCl2) (1 mol/L) and 4 carrier gas) with combustion of samples to carbon diox-
units thrombin and incubating at 22C for 1 hour. The ide at 1000C in a quartz column with oxygen (99.994%
fibrin clot was squeezed between two wooden rods and purity) introduction for 40 seconds. The dried, isolated
against the inside walls of the tube to remove trapped protein samples were transferred to tin capsules and
plasma. The clot was washed by mixing and centrifuging introduced into the system via an autosampler. The car-
it with 2 mL water and 2 mL 0.2 mol/L PCA, successively. bon dioxide from the combustion process then passed
Sodium dodecyl sulfate polyacrylamide gel electropho- through a water trap and was separated from all other
resis (SDS-PAGE) of the pellet showed less than 1% gases produced by a gas chromatograph set at 55C. The
contaminating bands, and commercially available human gas peaks subsequently flowed into a magnetic sector
fibrinogen compared favorably with the band obtained mass spectrometer for isotope analysis via computer con-
from experimental samples. The resulting pellet was ana- trol. The mass spectrometer’s precision was 0.2 per mil-
lyzed for l-(1-13C) leucine enrichment using combustion lion for 13C ratio analysis as stated by the manufacturer
isotope ratio mass spectrometry (Metabolic Solutions). and verified by multiple analyses of laboratory standards.
Enrichment measurements were made in duplicate, and Serum albumin was analyzed using bromcresol green
duplicates had a coefficient of variation of N  1%. technique; serum prealbumin by an antigen-antibody com-
Albumin was precipitated from plasma by adding 2 mL plex assay, serum transferrin by turbidimetric 12 reading
of 10% trichloroacetic acid (TCA) to the defibrinogen- and CRP was measured using nephelometric analysis. IL-6
ized plasma from above. The pellet was solublized in was measured by an enzyme-linked immunosorbent assay
0.5 mL water before adding 2.5 mL 96% ethanol con- (ELISA; ALPCO Diagnostic, Windham, NH, USA).
taining 1% TCA. After mixing and centrifugation, the
Calculationssupernatant was collected. Although the recovered sam-
ple contained90% of the albumin, SDS-PAGE showed The steady-state rates of whole-body leucine appear-
some contaminating bands. Removal of these bands was ance (Ra; an estimate of whole-body protein turnover)
accomplished via the addition of 2 mL 26.8% ammonium were calculated by dividing l-(1-13C) leucine infusion
sulfate. The ammonium sulfate precipitated the albumin, rate by the plasma (13C) KIC enrichment [29]. Plasma
but not the contaminating bands. The precipitate was KIC provides a better estimate of intracellular leucine en-
washed twice with 2 mL 0.2 mol/L PCA, and the resulting richment than plasma leucine enrichment because KIC
is derived from intracellular leucine metabolism [29].pellet was analyzed similar to fibrinogen using combus-
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Table 1. Demographic and nutritional characteristics of
the study patients (N  9)
Gender male/female 5/4
Age years 46.24.4
Race Caucasian/African American 4/5
Primary disease
Diabetes mellitus 2
Hypertension 5
Glomerulonephritis 1
Unknown 1
Nutritional parameters
Body weight kg 82.65.13
Serum albumin g/dL 4.180.14
Serum prealbumin mg/dL 41.33.96
Serum transferrin mg/dL 1849.8
Serum total cholesterol mg/dL 19413
Total carbon dioxide mmol/L 21.50.6
C-reactive protein mg/dL 1.010.22Fig. 3. (13C)ketoisocaproate (KIC) enrichments during the study pe-
IL-6 pg/mL 11.92.93riod. The data indicate steady-state conditions during each phase of
the study with slopes not statistically significantly different than zero.
(Statistical Analysis System for Windows, 1996, Release
Steady-state conditions existed for KIC and carbon diox- 8.12, SAS Institute, Cary, NC, USA). A P value 0.05
was required to reject the null hypothesis of no differenceide enrichments (Figs. 2 and 3), as evidenced by slopes
between the means. Pearson correlation was used tonot significantly different from zero. Our analysis dem-
analyze the associations between variables.onstrated that tracer/tracee ratio in the dialysate was
similar to that in plasma during the dialysis period (data
not shown). RESULTS
As shown in equation below, FSR for albumin and
Patients’ demographic and baseline nutritional charac-fibrinogen were calculated using the mean plasma KIC
teristics are depicted in Table 1. A total of nine subjectsenrichment (KICme) during each period as the tracer pre-
were enrolled in the study (five male and four femalecursor enrichment and the changes in enrichment of leu-
with a mean age of 46.2  4.4 years). The etiologies ofcine bound to the products (albumin and fibrinogen)
ESRD were diabetes mellitus (N 2), hypertension (Nduring each period. The KICme for each period was calcu-
5), glomerulonephritis (N  1), and unknown (N  1).lated as the average KIC enrichment of the time points
for each period. FSR of each of these proteins is ex- Baseline nutritional and inflammatory markers
pressed as percent synthesized per day. The change in
The baseline concentrations of nutritional and in-enrichment of the products is calculated by subtracting
flammatory markers for study subjects are included in
the product isotopic enrichment at the start of the period
Table 1 (mean  SE). The study patients were well-
(Psebackground for period) from the final product isoto-
nourished. The mean concentration for serum albumin
pic enrichment at the end of the period (Pfe). was 4.18  0.14 g/dL, serum pre-albumin 41.3  3.96
mg/dL, serum transferrin 184  9.8 mg/dL, and totalFSR (% per day)  {(Pfe  Pse )/t)/(KICme)} 	 100%
serum cholesterol 194 13 mg/dL. Baseline IL-6 concen-
In order to eliminate any potential artifact of inade- trations were significantly elevated compared to healthy
quate lag time, we calculated albumin and fibrinogen controls (11.9  2.93 pg/mL vs. 0.04  0.01 pg/mL, P 
FSR during hemodialysis using 120 minutes as the base- 0.05). Baseline mean CRP concentration was 1.01 0.22
line. The results were similar in both calculations (using mg/dL (range 0.3 to 2.0 mg/dL) in the study patients.
0 minute versus 120 minutes as baseline). Therefore, only There was a modest but statistically significant correla-
the results using 0 minute as baseline are reported. tion between baseline CRP and IL-6 concentrations (r
0.58, P  0.05). Baseline fibrinogen and albumin FSR
Statistical analysis were 11.2  0.9%/day and 7.4  1.3%/day, respectively
For each protocol, mean values for each period (basal, (Table 2). There were no correlations between baseline
dialysis, post-dialysis periods) were calculated. Values IL-6 concentrations and FSR of albumin as well as fi-
presented in the text and figures are means  SEM for brinogen.
each period. Comparisons within periods and differences
Effects of hemodialysis procedurebetween the mean values were assessed using repeated-
measures analysis of variance. Comparisons between Comparisons of IL-6 concentrations within each study
period did not reveal any significant differences. There-healthy controls and study subjects were done by t test
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Table 2. Component of hepatic protein synthesis, whole body protein breakdown and interleukin-6 (IL-6) levels during study periods
Hemodialysis Post-dialysis
Baseline (Change from baseline) (Change from baseline)
Albumin FSR %/day 7.41.3 12.21.3a 10.92.2
(4.81.6) (3.63.2)
Fibrinogen FSR %/day 11.20.9 15.11.7a 17.71.1a
(3.91.5) (6.51.6)
C-reactive protein mg/L 5.75 N/A 5.80
Median [range] [0.1 to 29.5] [0.4 to 34.4]
IL-6 pg/mL 11.92.93 13.63.58 20.02.6a,b
(1.71.4) (8.12.6)
IL-6 pg/mL (median) 12.7 10.7 16.5
[range] [1.3 to 26.4] [2.2 to 29.1] [6.1 to 27.7]a,b
Values reported are mean  SE of each period unless otherwise stated.
a Denotes significant difference from the baseline period (P  0.05)
b Denotes P  0.05 vs. hemodialysis
Fig. 5. The increment in fibrinogen fractional synthetic rates (FSR)Fig. 4. The increment in interleukin-6 (IL-6) concentration during each
during each study period for each individual patient. The mean isstudy period for each individual patient. The mean is depicted in bold.
depicted in bold. *Denotes significant difference from the baseline*Denotes significant difference from the baseline period for the mean
period (P  0.05) for the mean.(P  0.05); 
 denotes P  0.05 vs. hemodialysis for the mean.
There were also significant changes in albumin and
fore, the means of each study period were used for com- fibrinogen FSR during the hemodialysis procedure. Ta-
parisons between study periods. Mean IL-6 concentra- ble 2 shows the results for these parameters during the
tion measured during the hemodialysis procedure did three phases of the study. Both albumin FSR and fibrin-
not differ significantly from baseline levels, although ogen FSR increased significantly during the hemodialysis
there was a small numerical increase (11.9 2.93 pg/mL procedure compared to baseline (64% and 34%, respec-
vs. 13.6  3.58 pg/mL, P  NS). However, following tively, P  0.05 for both). Of note, during the 2-hour
completion of the hemodialysis procedure, there was a post-dialysis period, albumin FSR decreased slightly
statistically significant increase in IL-6 concentration com- compared to the hemodialysis period, although it was
pared to baseline (11.9  2.93 pg/mL vs. 20.0  2.6 still numerically higher than basal values (10.9  2.2%/
pg/mL, P 0.05). Figure 4 depicts mean IL-6 concentra- day post-dialysis vs. 7.4  1.3%/day baseline, P  NS).
tions during each study period for each individual pa- In contrast, fibrinogen FSR, shown in Table 2 and Figure
tient. The mean increase in IL-6 concentrations was 14% 5, increased further during the post-dialysis period com-
during the hemodialysis period, and 68% during the post- pared to the hemodialysis period (17%, 17.7  1.1%/
dialysis period compared to baseline period. Due to non- day during the post-hemodialysis vs. 15.1  1.7%/day
normal distribution (median and ranges depicted in Ta- during hemodialysis), but the difference did not achieve
ble 2), IL-6 levels were analyzed using non-parametric statistical significance. Thus, there was 58% increment in
analysis of variance. There was a statistically significant fibrinogen FSR observed during the post-dialysis period
increase during post-dialysis period compared to base- (17.7  1.1%/day) compared to baseline levels (11.2 
line and dialysis periods. Table 2 also depicts me- 0.9%/day), which was highly significant (P  0.01). The
dian (range) CRP levels at baseline and post-dialysis extent of change in fibrinogen FSR during post-dialysis
periods. For CRP, there was no statistically significant period was weakly correlated with the extent of change
in IL-6 levels (r  0.22)difference between these two periods of the study.
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DISCUSSION its circulating concentrations in cancer patients [36].
They also suggested that fibrinogen might be the mostThe results of this study clearly indicate that the hemo-
important APP in chronic inflammation. Based on thisdialysis procedure induces an inflammatory reaction that
information, we believe that examination of these mark-becomes evident particularly during the 2-hour period
ers during and after hemodialysis would be sufficient tofollowing termination of dialysis. This is evidenced by the
assess inflammatory response in our study.significant increase observed in fibrinogen FSR during
The present study showed a significant increase inhemodialysis, followed by concomitant increases in both
fibrinogen FSR during the hemodialysis procedure. TheIL-6 concentrations and fibrinogen FSR during the 2-hour
fractional synthetic rate is considered a more reliablepost-hemodialysis period. To our knowledge, this is the
parameter than the absolute synthetic rate, because de-most clear-cut indication of an inflammatory response
termination of the absolute sysnthetic rate requires anto the hemodialysis procedure utilizing a novel technique
accurate measurement of plasma volume and concentra-to measure acute-phase response.
tions; unfortunately, plasma volume and concentrationsIt is generally well accepted that inflammation may
are highly variable in hemodialysis patients because ofcontribute both to malnutrition and clinical outcome in
extracellular volume contraction during hemodialysis.chronic hemodialysis patients. The evidence of inflam-
FSR reflects the portion of the total pool that is synthe-mation has been observed in chronic renal failure pa-
sized per unit of time. Of importance, this is not affectedtients even before the initiation of dialysis treatment
by changes in fluid volume. Therefore, the increase inas well as after initiation of hemodialysis or peritoneal
fibrinogen FSR observed in our studies reflects an actualdialysis [1, 3, 7, 32]. While factors unrelated to dialysis
increase in fibrinogen synthesis and indicates an acute-therapy such as uremic milieu and co-morbidities might
phase response regardless of other conditions that mayalso induce acute-phase response [6, 8], our results indi-
influence its absolute values. This increase in fibrinogencate that the hemodialysis procedure itself specifically
synthesis may also contribute to the elevated fibrinogencontributes to the inflammatory state in chronic hemodi-
concentration observed in chronic hemodialysis patients
alysis patients. Given the clear association of inflamma-
[3, 25, 26].
tion with several indicators of poor clinical outcome, An interesting observation in our study is that albumin
protein calorie malnutrition and cardiovascular disease, FSR was significantly increased during hemodialysis treat-
the clinical relevance of this finding is critical. On the ment despite the development of the inflammatory reac-
other hand, the cumulative effect of this process and tion. Since albumin is considered a negative APP, one
overall contribution to the chronically inflamed state ob- could expect its FSR to decrease in the presence of in-
served in chronic hemodialysis patients must be evalu- flammation. The concentration of serum albumin is de-
ated by further studies. termined by the rate of its synthesis, degradation rate,
Inflammation, more correctly termed “systemic in- and redistribution. Inflammation has been considered a
flammatory response syndrome“ (SIRS), is a sequence determinant of serum albumin concentration in hemodi-
of events initiated in reaction to a stimulus that causes alysis patients [37]. Several investigators reported con-
tissue injury or disease. These events involve a series flicting results concerning albumin synthesis during in-
of signals that mediate these effects, primarily through flammation [27, 38–40]. It is generally accepted that low
cytokines and acute phase proteins (APPs). In this study, albumin levels results from decreased albumin synthesis.
in order to evaluate the inflammatory cascade, we mea- However, Ruot et al reported that albumin FSR was
sured IL-6, a first-line cytokine that is thought to play a increased during infection and low levels of plasma albu-
central role in SIRS, and separately the fractional pro- min could be present without a decrease in albumin
duction rates of two APPs, albumin and fibrinogen. synthesis in rats [40]. In a study by Fearon et al, a 34%
While other cytokines, such as IL-1, tumor necrosis fac- increase in albumin synthesis rate was reported in cancer
tor alpha (TNF-), and other APPs, could also be in- patients with hypoalbuminemia [41]. Similarly, Mansoor
volved in this inflammatory cascade, measurement of et al reported a 60% increase in albumin FSR in head
IL-6 and fibrinogen FSR are considered satisfactory indi- trauma patients with inflammation. Our results are con-
ces reflecting the acute-phase response [22–24, 27, 33, 34]. sistent with this hypothesis [27]. Indeed, our report is
Several inflammatory processes are mediated by IL-6, the first evidence of this finding in chronic hemodialysis
which is directly regulating many of the acute-phase re- patients during the hemodialysis procedure and although
actant proteins. The other two important proinflamma- it is counterintuitive, is nevertheless true and consistent
tory cytokines, TNF- and IL-1, can also induce IL-6 with current literature. Overall, these studies suggest that
[24, 35]. Fibrinogen is one of the positive APPs and its while albumin FSR may be increased during inflamma-
synthesis during inflammation is correlated with IL-6 tion, there are other factors that determine plasma albu-
[22, 27]. Preston et al reported that there are significant min concentrations during this altered metabolic state.
Another potential stimulator of albumin synthesis iscorrelations between the fibrinogen synthetic rate and
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increased protein breakdown. Indeed, we have pre- studies reporting lack of increase in acute-phase re-
actants with the use of biocompatible membranes didviously reported that whole body protein breakdown is
increased during and after hemodialysis in the similar not examine the 2-hour post-dialysis period, in which we
were able to show an increase in IL-6 concentrationspatient population [42]. Therefore, it is possible that
inflammation leads to a decrease in serum albumin levels and fibrinogen FSR.
We have previously reported that whole body andwithout decreasing its FSR, and that an increase in whole
body protein breakdown and the loss of amino acids muscle protein breakdown demonstrated a linear in-
crease during hemodialysis and the subsequent 2-hourinto dialysate during hemodialysis session may lead to
compensatory increase in albumin synthesis, particularly post-hemodialysis period [42]. The findings of concomi-
tant increment of inflammatory markers, along with thein well-nourished patients. On the other hand, malnour-
ished patients might not be able to respond similarly [43]. increase in protein breakdown during the post-dialysis
period, suggest that these two observations are relatedAn additional possible explanation of increased albumin
FSR in our study is the acute correction of acidosis during and there might be a cause and effect relationship be-
tween inflammation and increased protein breakdown.hemodialysis. While there are several conflicting reports
on the effect of acidosis on albumin synthesis, this mecha- Indeed, the protein catabolic effects of acute inflamma-
tion are well known and studies have shown that IL-6nism may lead to an increase in albumin FSR, but re-
quires further research for confirmation [44, 45]. induces muscle catabolism and this effect is prevented
by the administration of IL-6 antibody [54]. It was alsoSeveral factors can be responsible for the hemodialy-
sis-associated inflammatory response. Endotoxin expo- suggested that IL-6 might cause proteolysis by activating
ubiquitin proteasome pathway and by increasing cathep-sure (or its bioactive fragments) crossing from the dialy-
sate to the blood compartment is one potential factor sin activity [54–57]. Of note, our findings are compatible
with the studies by Gutierrez et al who reported an[46]. Prospective longitudinal studies by Panichi et al and
Ronco et al elegantly showed the increase in inflamma- increase in amino acid breakdown approximately 6 hours
tory markers with the use of hemodialysis techniques after initiation of hemodialysis in normal volunteers [10].
allowing dialysate backfiltration [47, 48]. In parallel, two Clearly, our results are only suggestive and should
recent studies reported that on-line produced ultra-pure prompt the need for further studies on this subject.
dialysate significantly decreased IL-6 and CRP concen- While the results presented in this study are intriguing,
trations [49, 50]. While the hypothesis put forward by some potential limitations should be considered. Our
these investigators, that is, that the hemodialysis proce- study population was well nourished and the results may
dure may trigger an inflammatory response is confirmed be different in malnourished chronic hemodialysis pa-
by our study utilizing novel techniques, the current study tients, who potentially may have a different response to
does not provide a mechanistic explanation of this find- inflammatory stimuli. These studies should be extended
ing. Although our sampling of dialysate for endotoxin to a larger patient population with a more diverse nutri-
was consistently negative using Limulus-Amebocyte Ly- tional status. It is also clear that this study represents
sate (Biowhittaker, Inc., Walkersville, MD, USA), the only short-term effects of one hemodialysis procedure,
inflammatory reaction observed in this study can still be and it would only be speculative to project the effect of
secondary to backfiltration of low levels or small frag- repetitive hemodialysis over a longer period of time
ments of endotoxin. This issue needs to be studied fur- based on this report. While the techniques used in this
ther, especially with the availability of ultra-pure dialy- study are associated with a margin of error, these are
sate. small and the techniques are well accepted and validated.
Hemodialysis membrane bioincompatibility is another In addition, we have used these techniques in several
potential cause for the development of inflammatory re- study populations and have found them to be reliable
action during the hemodialysis procedure. Specifically, and reproducible [30, 58, 59]. Finally, it should be
hemodialysis membranes that activate the complement re-emphasized that only one type of hemodialysis mem-
system are thought to induce the inflammatory cascade brane and typical dialysate was used in this study.
[20, 51]. Although there are conflicting reports with re-
gard to the relative effects of the different membrane
CONCLUSIONtypes on the activation of the acute-phase response [15,
Our results clearly indicate that the hemodialysis pro-20, 51, 52], it is generally accepted that biocompatible
cedure induces an acute inflammatory reaction, which ismembranes have less of an effect on the development of
further exacerbated during the 2-hour period followingthe acute-phase response compared to bioincompatible
completion of hemodialysis. This is evidenced by themembranes. It should be noted while synthetic mem-
increase observed in fibrinogen FSR during hemodialy-branes, as the ones used in this study, are termed “bio-
sis, followed by concomitant increases in both IL-6 con-compatible,” they nevertheless induce the complement
cascade, albeit at a lower magnitude [53]. Further, most centrations and fibrinogen FSR during 2-hour post-hemo-
Caglar et al: Hemodialysis-induced inflammation 1415
ysis membrane on the inflammatory reaction in vivo. Clin Nephroldialysis period. This phenomenon may contribute to net
53:452–459, 2000
protein catabolism observed in chronic hemodialysis pa- 19. Girndt M, Heisel O, Kohler H: Influence of dialysis with polyam-
ide haemophan haemodialysers on monokines and complementtients patients.
activation during a 4-month long-term study. Nephrol Dial Trans-
plant 14:676–682, 1999
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